Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Short-Term Debt issuances (2017 - 2021)

Ani Pharmaceuticals' Short-Term Debt issuances history spans 5 years, with the latest figure at $262.0 million for Q4 2021.

  • For Q4 2021, Short-Term Debt issuances rose 1846.88% year-over-year to $262.0 million; the TTM value through Dec 2021 reached $286.0 million, changed N/A, while the annual FY2021 figure was $286.0 million, N/A changed from the prior year.
  • Short-Term Debt issuances for Q4 2021 was $262.0 million at Ani Pharmaceuticals, up from $24.0 million in the prior quarter.
  • Across five years, Short-Term Debt issuances topped out at $262.0 million in Q4 2021 and bottomed at -$15.0 million in Q4 2020.
  • The 3-year median for Short-Term Debt issuances is $19.5 million (2020), against an average of $51.8 million.
  • The largest YoY upside for Short-Term Debt issuances was 1846.88% in 2021 against a maximum downside of 1846.88% in 2021.
  • A 3-year view of Short-Term Debt issuances shows it stood at -$5.0 million in 2017, then tumbled by 200.0% to -$15.0 million in 2020, then surged by 1846.88% to $262.0 million in 2021.
  • Per Business Quant, the three most recent readings for ANIP's Short-Term Debt issuances are $262.0 million (Q4 2021), $24.0 million (Q2 2021), and -$15.0 million (Q4 2020).